Terns Pharmaceuticals (TERN) Stock Overview
A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TERN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Terns Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.47 |
| 52 Week High | US$18.75 |
| 52 Week Low | US$1.87 |
| Beta | -0.026 |
| 1 Month Change | 123.61% |
| 3 Month Change | 203.78% |
| 1 Year Change | 153.01% |
| 3 Year Change | 273.13% |
| 5 Year Change | n/a |
| Change since IPO | 0.43% |
Recent News & Updates
Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Oct 22Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Sep 19
Recent updates
Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Oct 22Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Sep 19Terns Pharma: I Don't See The Positioning
Feb 08We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Feb 06Terns Pharmaceuticals: Another Potential GLP-1 Entrant
Oct 21Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Sep 25Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Sep 10We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Shareholder Returns
| TERN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 123.6% | 2.0% | -2.0% |
| 1Y | 153.0% | 4.4% | 12.1% |
Return vs Industry: TERN exceeded the US Pharmaceuticals industry which returned 6.8% over the past year.
Return vs Market: TERN exceeded the US Market which returned 12.3% over the past year.
Price Volatility
| TERN volatility | |
|---|---|
| TERN Average Weekly Movement | 22.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TERN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TERN's weekly volatility has increased from 15% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 59 | Amy Burroughs | www.ternspharma.com |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Terns Pharmaceuticals, Inc. Fundamentals Summary
| TERN fundamental statistics | |
|---|---|
| Market cap | US$1.60b |
| Earnings (TTM) | -US$91.74m |
| Revenue (TTM) | n/a |
Is TERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TERN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$91.75m |
| Earnings | -US$91.74m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TERN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 05:51 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Etzer Darout | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |